# Akso Health Group > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Akso Health Group). ## Overview Akso Health Group is a U.S.-incorporated holding company with operating subsidiaries in the United States and China that sell medical devices and offer healthcare-related services. Its business has included products such as defibrillators, anesthesia laryngoscopes, and COVID-19 rapid antigen test kits, alongside marketing promotion and online healthcare service activities tied to the healthcare sector. ## Products & services • Medical device sales, including defibrillators • Medical device sales, including anesthesia laryngoscopes • COVID-19 rapid antigen test kit distribution • Marketing promotion services for insurance-related clients • Online healthcare services and health consulting initiatives - **Medical devices** (45%) — Sales of devices such as defibrillators and anesthesia laryngoscopes to dealers and end users. - **Diagnostic and test kits** (10%) — Distribution of COVID-19 rapid antigen test kits through U.S. channels. - **Marketing promotion services** (40%) — Contracted promotion and order-based services for insurance carriers and intermediaries. - **Online healthcare services** (5%) — Healthcare-service initiatives and platform-based offerings for medical and consulting partners. - Medical device sales, including defibrillators - Medical device sales, including anesthesia laryngoscopes - COVID-19 rapid antigen test kit distribution - Marketing promotion services for insurance-related clients - Online healthcare services and health consulting initiatives ## Customers Akso sells medical devices to medical product dealers and to end users such as hospitals, while its U.S. test-kit business serves distributors. In China, its marketing promotion services are sold to insurance carriers and insurance intermediaries, and its healthcare-service initiatives target companies involved in health consulting and medical device sales. The customer mix is concentrated and project-based, with some relationships governed by multi-year cooperation agreements and others transacted on an order-by-order basis. - **Medical product dealers** (primary) — Buy defibrillators and laryngoscopes for resale into healthcare channels. - **Hospitals and end users** (primary) — Purchase medical devices for direct clinical use and procurement needs. - **Insurance carriers and intermediaries** (primary) — Buy marketing promotion services under cooperation agreements in China. - **U.S. distributors** (secondary) — Purchase COVID-19 rapid antigen test kits for downstream distribution. - **Healthcare technology partners** (secondary) — Engage for online healthcare and consulting-related service initiatives. - Medical product dealers buying devices for resale - Hospitals and end users purchasing clinical equipment - U.S. distributors buying rapid antigen test kits - Insurance carriers and intermediaries buying promotion services - Healthcare-service partners seeking consulting or platform support ## Geography Akso is structured across the United States and Greater China, with U.S. entities used for test-kit distribution and Chinese subsidiaries used for medical device sales and healthcare-related services. The reports also show entities in Wyoming, Shandong, Tianjin, Hong Kong, and the British Virgin Islands, reflecting a cross-border operating and holding-company structure. Geography matters because product sales, service contracts, and regulatory regimes differ materially between the U.S. and China. - United States entity handles rapid antigen test kit sales - China entities sell medical devices and provide services - Hong Kong and BVI subsidiaries support the corporate structure - Wyoming, Shandong, and Tianjin are key operating locations - Cross-border operations create different regulatory exposures ## Strategy Akso’s stated direction is to build healthcare-related businesses around medical devices, online healthcare services, and adjacent promotion/service arrangements. The company has also used subsidiary formation and market entry in China and the U.S. to broaden its operating base and develop multiple revenue streams. Its reported initiatives suggest a strategy of pursuing healthcare-sector opportunities where it can combine product distribution with service relationships. - **Build a broader healthcare portfolio** (medium-term) — Reduces dependence on any one product or service line and increases optionality. - **Develop China operating relationships** (short-term) — China is central to the company's device and service activity and partner access. - **Maintain cross-border distribution channels** (medium-term) — U.S. and China channels support different customer sets and revenue sources. - Expand healthcare-related revenue streams beyond a single product line - Use China-based subsidiaries to build local operating reach - Retain U.S. distribution capability for test-kit sales - Develop service relationships with insurance and health partners - Pursue tailored healthcare offerings through cooperative agreements ## Risks Akso’s business is exposed to customer concentration, regulatory compliance, and execution risk across multiple business lines. Its healthcare and marketing activities involve medical, data, and contractual requirements, while goodwill impairment and acquisition-related issues show that valuation and integration judgments can materially affect results. Cross-border operations also increase exposure to U.S. and PRC legal, licensing, and operational risks. - **Customer concentration** [high] — A few customers accounted for a large share of marketing service revenue and receivables. - **Healthcare regulatory compliance** [high] — Medical device sales and online healthcare services are subject to health, privacy, and licensing rules. - **Goodwill impairment** [high] — The company recorded a material impairment tied to lower projected revenue growth and profitability assumptions. - **Medical liability claims** [high] — Online healthcare and medical-related activities can trigger claims for service errors or patient harm. - **Cross-border execution** [medium] — Operating through multiple subsidiaries across jurisdictions increases legal and operational complexity. - High customer concentration in marketing promotion services - Medical and healthcare regulation risk in the U.S. and China - HIPAA and related privacy/compliance exposure - Goodwill and acquired asset impairment risk - Execution risk in building new healthcare service lines ## Accounting The most important accounting issue is goodwill and asset impairment, because the company relies on management forecasts to test recoverability and fair value of reporting units and asset groups. Revenue can also be judgmental because the business uses customer contracts, weekly service fees, and distributor sales across different lines, each with different recognition patterns. Investors should also watch estimates tied to receivables, fair value assumptions, and any contingent liabilities linked to healthcare operations or compliance matters. - **Goodwill impairment** — Can create large non-cash charges when forecasts weaken - **Revenue recognition** — Affects timing and comparability of revenue across periods - **Accounts receivable collectability** — Can affect net receivables and bad-debt expense - **Fair value estimates** — Influences impairment conclusions and balance-sheet carrying values - Goodwill impairment testing uses forecasted cash flows and fair value assumptions - Asset recoverability depends on projected revenue growth and profitability - Service-fee revenue recognition depends on contract terms and order timing - Receivables may be concentrated and require collectability judgment - Healthcare compliance matters can create contingent liabilities or reserves --- *Last updated: 2026-09-28T11:57:37.924920+00:00*